ArticleAutoimmunity reviews2020
Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection.
Article in Autoimmunity reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Is endogenous carboxyhaemoglobin level a useful biomarker of clinical course and prognosis in COVID-19 patients?International journal of clinical practice · 2021Article
- Cardiovascular Disease Complicating COVID-19 in the Elderly.Medicina (Kaunas, Lithuania) · 2021Review
- What do we know about IL-6 in COVID-19 so far?Biophysics reports · 2021Article
- Will Auranofin Become a Golden New Treatment Against COVID-19?Frontiers in immunology · 2021Review
- COVID-19 and immune-mediated inflammatory diseases: Why don't our patients get worse?Autoimmunity reviews · 2020Article
- Therapeutic Strategies in the Development of Anti-viral Drugs and Vaccines Against SARS-CoV-2 Infection.Molecular neurobiology · 2020Review
- Covid-19 and autoimmunity.Autoimmunity reviews · 2020Review
- Overcoming Barriers: The Endothelium As a Linchpin of Coronavirus Disease 2019 Pathogenesis?Arteriosclerosis, thrombosis, and vascular biology · 2020Review
- Re: Patiently waiting for the results of anti-IL 6 therapy in severe COVID-19 infection.Autoimmunity reviews · 2020Article
- Allergo Journal : interdisziplinare Zeitschrift fur Allergologie und Umweltmedizin : Organ der Deutschen Gesellschaft fur Allergie- und Immunitatsforschung · 2020Review
- Can Natural Killer Cells Be a Principal Player in Anti-SARS-CoV-2 Immunity?Frontiers in immunology · 2020Article
- Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärzteverband Deutscher Allergologen (AeDA)Allergologie select · 2020Article
- Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines.Molecular biomedicine · 2020Review
Corrections and comments
- Commented on by
- Comment on
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.